Clinical Trial Update: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of AC699 in ER+/HER2- locally advanced or metastatic breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AC699

Snippet

Sponsor: Accutar Biotechnology Inc | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING